infohep news

• Hepatocellular carcinoma (HCC)

  Immunotherapy combination improves liver cancer survival

  Liz Highleyman / 27 November 2019

  A combination of nivolumab (Opdivo) and ipilimumab (Yervoy), two different types of checkpoint inhibitor immunotherapy, led to higher response rates and longer survival than nivolumab alone in people with advanced liver cancer, according to a ...

• Experimental treatments for NASH/NAFLD

  New NASH therapies show promise in mid-stage studies

  Liz Highleyman / 26 November 2019

  Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ...

• NAFLD

  People with fatty liver disease struggle to lose weight

  Liz Highleyman / 25 November 2019

  Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can succeed and doing so improves liver health, according to studies ...

• Hepatocellular carcinoma (HCC)

  Sustained response to HCV antivirals boosts liver cancer survival

  Liz Highleyman / 19 November 2019

  People with liver cancer who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy for hepatitis C saw a reduction in both liver-related and all-cause mortality over five years, according to ...

• Hepatocellular carcinoma (HCC)

  Hepatitis B antiviral drugs reduce liver cancer risk

  Liz Highleyman / 19 November 2019

  Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ...